Charles Schwab Investment Management Inc. Decreases Position in MediWound Ltd. (NASDAQ:MDWD)

Charles Schwab Investment Management Inc. reduced its position in shares of MediWound Ltd. (NASDAQ:MDWD) by 7.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,125 shares of the biopharmaceutical company’s stock after selling 1,603 shares during the period. Charles Schwab Investment Management Inc. owned 0.18% of MediWound worth $345,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in MDWD. Rhumbline Advisers acquired a new stake in shares of MediWound in the second quarter worth approximately $131,000. Bank of New York Mellon Corp purchased a new position in MediWound in the 2nd quarter valued at $342,000. ARK Investment Management LLC acquired a new stake in MediWound during the 3rd quarter worth $1,806,000. Finally, Rosalind Advisors Inc. grew its holdings in shares of MediWound by 22.3% during the third quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after buying an additional 114,560 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Stock Performance

NASDAQ:MDWD opened at $17.20 on Friday. MediWound Ltd. has a one year low of $10.06 and a one year high of $24.00. The stock has a market cap of $185.52 million, a PE ratio of -5.93 and a beta of 0.81. The stock has a 50 day moving average price of $17.29 and a 200 day moving average price of $17.42.

MediWound (NASDAQ:MDWD) last issued its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the previous year, the firm earned ($0.24) earnings per share. As a group, analysts predict that MediWound Ltd. will post -2.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price target on shares of MediWound from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, November 27th.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.